

Monika DÅ,ugosz-Danecka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6667442/publications.pdf>

Version: 2024-02-01

63
papers

895
citations

566801

15
h-index

500791

28
g-index

65
all docs

65
docs citations

65
times ranked

1476
citing authors

#	ARTICLE	IF	CITATIONS
1	Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. <i>Haematologica</i> , 2022, 107, 1086-1094.	1.7	24
2	Outcome of SARS-CoV-2-Infected Polish Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022, 14, 558.	1.7	6
3	Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2022, 387, 310-320.	13.9	98
4	Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1066-1076.	0.6	3
5	Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 455-463.	1.4	24
6	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	0.6	1
7	Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7525-7525.	0.8	1
8	Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e410-e421.	2.2	83
9	Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study. <i>Blood</i> , 2021, 138, 3726-3726.	0.6	3
10	Safety and Early Efficacy of Obinutuzumab in Combination with Chemotherapy in Treatment Naive Patients with Follicular Lymphoma - Report of Polish Lymphoma Research Group (PLRG). <i>Blood</i> , 2021, 138, 4525-4525.	0.6	0
11	The Selective Bruton Tyrosine Kinase (BTK) Inhibitor TG-1701 As Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-Cell Malignancies. <i>Blood</i> , 2021, 138, 1549-1549.	0.6	4
12	Outcomes of treatment with dose-adjusted EPOCH or R-CHOP in primary mediastinal large B-cell lymphoma. <i>European Journal of Haematology</i> , 2020, 104, 59-66.	1.1	25
13	Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). <i>British Journal of Haematology</i> , 2020, 188, 240-248.	1.2	17
14	Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00649.	1.1	2
15	Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study. <i>Anticancer Research</i> , 2020, 40, 4059-4066.	0.5	8
16	Efficacy of high-dose corticosteroid-based treatment for chronic lymphocytic leukemia patients with p53 abnormalities in the era of B-cell receptor inhibitors. <i>Advances in Medical Sciences</i> , 2020, 65, 371-377.	0.9	2
17	Cardio-oncology for better lymphoma therapy outcomes. <i>Lancet Haematology</i> , 2020, 7, e273-e275.	2.2	1
18	Rituximab biosimilars in clinical practice. <i>Leukemia and Lymphoma</i> , 2020, 61, 1523-1524.	0.6	1

#	ARTICLE	IF	CITATIONS
19	Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP – the PLRG report. <i>Scientific Reports</i> , 2020, 10, 3517.	1.6	12
20	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	2.0	11
21	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	0.6	3
22	Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study. <i>Blood</i> , 2020, 135, 735-742.	0.6	86
23	Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. <i>Blood</i> , 2020, 136, 37-39.	0.6	37
24	Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. <i>Blood</i> , 2020, 136, 26-28.	0.6	5
25	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Long-Term Efficacy and Safety Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 38-39.	0.6	5
26	A Phase 1, Open-Label Study of MGD013, a Bispecific DART [®] Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 21-22.	0.6	13
27	Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis. <i>Chemotherapy</i> , 2019, 64, 155-162.	0.8	0
28	Rituximab biosimilars for lymphoma in Europe. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1045-1056.	1.4	13
29	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , 2019, 33, 2762-2766.	3.3	67
30	Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. <i>Leukemia and Lymphoma</i> , 2019, 60, 1610-1625.	0.6	16
31	Consolidation with ⁹⁰ Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. <i>Leukemia and Lymphoma</i> , 2019, 60, 2689-2696.	0.6	6
32	The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients. <i>Cancer Medicine</i> , 2019, 8, 1103-1109.	1.3	15
33	Avatrombopag for the treatment of immune thrombocytopenia. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 327-339.	1.3	12
34	Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma – Polish Lymphoma Research Group real-life analysis. <i>Pharmacological Reports</i> , 2019, 71, 473-477.	1.5	3
35	Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. <i>Oncology. Seminars in Oncology</i> , 2019, 46, 397-402.	0.8	16
36	Acalabrutinib for adults with mantle cell lymphoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 179-187.	1.3	9

#	ARTICLE	IF	CITATIONS
37	The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. <i>Future Oncology</i> , 2019, 15, 305-317.	1.1	5
38	Improved Treatment Outcomes for Patients with Hodgkin Lymphoma Relapsing after Autologous Hematopoietic Stem Cell Transplantation in the Brentuximab Vedotin Era - the Real-Life Report from the Polish Lymphoma Research Group. <i>Blood</i> , 2019, 134, 5276-5276.	0.6	1
39	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. <i>Oncology Letters</i> , 2019, 18, 5811-5820.	0.8	4
40	The necessity of post-induction therapy in mantle cell lymphoma patients: A multicenter retrospective real-world analysis by Polish Lymphoma Research Group (PLRG). <i>Postępy Higieny i Medycyny Doswiadczałnej</i> , 2019, 73, 303-309.	0.1	1
41	Role of biomarkers and electrocardiography assessment as individual predictors of anthracycline cardiotoxicity in lymphoma patients. <i>OnCOReview</i> , 2019, 8, 99-104.	0.1	0
42	Hypoalbuminemia as a relapse risk factor after high dose chemotherapy and autologous stem cell transplantation in patients with Hodgkin lymphoma. <i>OnCOReview</i> , 2019, 8, 114-119.	0.1	0
43	Early chemotherapy de-escalation strategy in advanced-stage Hodgkin lymphoma patients with negative positron emission tomography scan after two escalated BEACOPP cycles. <i>Polish Archives of Internal Medicine</i> , 2019, 129, 259-266.	0.3	0
44	Evaluation of the prognostic and predictive value of free light chains in patients with chronic lymphocytic leukemia – preliminary results. <i>Acta Haematologica Polonica</i> , 2019, 50, 15-20.	0.1	0
45	Brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma: Three-year update of the ECHELON-1 study. <i>Journal of Clinical Oncology</i> , 2019, 37, 7532-7532.	0.8	2
46	Chłoniak z komórek piaszcza – rola terapii celowanych. <i>Acta Haematologica Polonica</i> , 2019, 50, 116-120.	0.1	0
47	Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study. <i>Blood</i> , 2019, 134, 4026-4026.	0.6	0
48	The Phase 3 Study ECHELON-1 Evaluating Brentuximab Vedotin in Patients With Newly Diagnosed Hodgkin Lymphoma Leaves Important Questions Unanswered. <i>HemaSphere</i> , 2018, 2, e52.	1.2	3
49	Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen. <i>Chemotherapy</i> , 2018, 63, 238-245.	0.8	17
50	Resolution of Peripheral Neuropathy (PN) in Patients Who Received A+AVD or ABVD in the Phase 3 ECHELON-1 Trial. <i>Blood</i> , 2018, 132, 2921-2921.	0.6	2
51	Older Patients (pts) with Previously Untreated Classical Hodgkin Lymphoma (cHL): A Detailed Analysis from the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018, 132, 1618-1618.	0.6	10
52	Brentuximab Vedotin Alone and in Combination with Bendamustine As Salvage Therapy for Primary Refractory or Relapsed Hodgkin Lymphoma: Multicentre Experience of the Polish Lymphoma Research Group (PLRG). <i>Blood</i> , 2018, 132, 5375-5375.	0.6	1
53	Brentuximab Vedotin Plus Chemotherapy in Patients with Advanced-Stage Classical Hodgkin Lymphoma (cHL): Evaluation of Modified Progression-Free Survival (mPFS) and Traditional PFS in the Phase 3 ECHELON-1 Study. <i>Blood</i> , 2018, 132, 2904-2904.	0.6	4
54	Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities – Polish Adult Leukemia Group (PALG) real-life analysis. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 421-426.	0.3	8

#	ARTICLE	IF	CITATIONS
55	Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG). <i>Anticancer Research</i> , 2018, 38, 3025-3030.	0.5	7
56	Efficacy and safety of obinutuzumab in the frontline treatment of CLL patients with comorbidities: The real-world results of Polish Adult Leukemia Group (PALG) retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19513-e19513.	0.8	0
57	The average relative dose intensity of R-CHOP as an independent prognostic factor determining overall survival in diffuse large B cell lymphoma patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19542-e19542.	0.8	0
58	Nivolumab for relapsed/refractory classical Hodgkin lymphoma after brentuximab vedotin failure – Polish Lymphoma Research Group real-life experience. <i>Acta Haematologica Polonica</i> , 2018, 49, 228-233.	0.1	1
59	Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders. <i>International Journal of Cardiology</i> , 2017, 235, 147-153.	0.8	8
60	Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent <i>CARD11</i> mutations. <i>Oncotarget</i> , 2016, 7, 38180-38190.	0.8	130
61	Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 791-799.	2.3	53
62	Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 589-595.	0.3	6
63	Ocena profilu korzyści i ryzyka leczenia idelalizybem u chorych na przewlekłą, biaczkę™ limfocytową i chłoniaki nie-Hodgkina. <i>Hematologia</i> , 0, , .	0.0	0